REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021

Aug 20, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-08-18

Reporting Person: SCHLEIFER LEONARD S (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-18	Common Stock	S	200000	$650.03	Disposed	304746	Direct
2021-08-19	Common Stock	S	10000	$660.03	Disposed	21178	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	200000	Indirect
Common Stock	5874	Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: Represents volume-weighted average price of sales of 200,000 shares of Company stock on August 18, 2021 at prices ranging from $650.00 to $650.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 18, 2021 at each separate price.

F3: Represents volume-weighted average price of sales of 10,000 shares of Company stock on August 19, 2021 at prices ranging from $660.00 to $660.13. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 19, 2021 at each separate price.

F4: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust.